Skip to content

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit

Status
Terminated
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02025855
Enrollment
9
Registered
2014-01-01
Start date
2014-01-31
Completion date
2017-10-31
Last updated
2025-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delirium, Opioid-Induced Disorders, Opioid Use, Unspecified With Withdrawal

Keywords

Iatrogenic opioid abstinence syndrome, Methadone, Mechanical ventilation, ICU delirium, Continuous sedation

Brief summary

The purpose of this study is to determine if administering methadone to mechanically ventilated patients in the medical intensive care unit (ICU) requiring continuous infusions of sedatives and analgesics will decrease the time of mechanical ventilation, when initiated within 48 hours of their admission. Patients meeting enrollment criteria will be randomly assigned to receive methadone or placebo in addition to standard care. Methadone is a long acting pain medication that is approved by the Food and Drug Administration (FDA) to manage withdrawal from opioids and moderate to severe pain. Both of these indications are a frequent concern for critically ill patients that require mechanical ventilation. These patients often require intravenous (IV) opioids to manage the pain they experience due to their illness, procedures, and mechanical ventilation. During this time patients can develop physical dependence, which leads to withdrawal symptoms when the opioids are stopped or the dose is reduced. These symptoms can include agitation, pain, diarrhea and several others. Currently this is managed by a slow reduction in the dose of the IV opioid, but this can lead to prolonged time on mechanical ventilation, which has been associated with increased morbidity. Administering oral methadone to patients experiencing withdrawal symptoms has been shown to reduce and even eliminate these symptoms in the outpatient setting. This should also benefit patients in the ICU experiencing withdrawal from intravenous opioids required during their stay. It may allow for the other opioids to be discontinued more quickly, allowing for a shorter duration of mechanical ventilation. The level of pain and sedation will be assessed between groups randomized to either methadone or placebo in addition to current intravenous sedative and analgesic agents. The duration of mechanical ventilation will be assessed between both groups. Opioid withdrawal symptoms may manifest or be mistaken for delirium symptoms. ICU delirium is often managed with antipsychotic medications. To assess if methadone can reduce the need for antipsychotic medication, all administered antipsychotic doses will be recorded and total consumption will be compared between the two groups. Methadone has been associated with abnormal heart rhythms in rare instances. To ensure patient safety, data from the heart monitor will be collected and compared between the two groups to assess for QT interval prolongation.

Interventions

DRUGMethadone
DRUGPlacebo

Sponsors

Henry Ford Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Mechanically ventilated patients with opioid consumption greater than or equal to 1,200 mcg of fentanyl or equivalent consumption of another opioid per day during the first 48 hours of intubation.

Exclusion criteria

* Allergy to methadone * Admitted for head injury * Admitted for seizure * Seizure during admission, prior to enrollment * Subjects at high risk for developing a prolonged corrected QT (QTc) interval * Gastric residual volume ≥200 mL * Suspected obstruction or ileus * Nausea and vomiting * Recent abdominal surgery * Active upper or lower gastrointestinal bleeding * Active order for no medications by mouth or Total parenteral nutrition (TPN) * Pregnancy * Subjects receiving neuromuscular blocker infusions * Subjects taking antipsychotics at baseline

Design outcomes

Primary

MeasureTime frameDescription
Time to ExtubationUp to 14 daysThe time to extubation will be calculated and compared for both groups.

Secondary

MeasureTime frameDescription
Cumulative Opioid ConsumptionUp to 14 daysCumulative doses of opioids will be collected and converted to morphine equivalents for analysis.
Level of SedationUp to 14 daysLevels of pain and sedation will be assessed per institutional policy, which utilizes the Motor Agitation Assessment Scale (MAAS). Average daily scores will be collected and compared for each group. The MAAS is scored from 0 (patient unresponsive) to 6 (dangerously agitated, uncooperative patient).
Cumulative Benzodiazepine ConsumptionUp to 14 daysDoses of all benzodiazepines will be collected and compared between groups to determine if methadone reduces consumption.
Corrected QT IntervalUp to 14 daysQTc intervals will be calculated and documented at baseline and every 24 hours after to ensure it does not become prolonged. These values will be compared between groups by taking the median of the baseline and daily values.
Cumulative Antipsychotic UseUp to 14 daysThe number of doses of antipsychotic medications will be collected and compared as a surrogate marker for presumed delirium.

Countries

United States

Participant flow

Participants by arm

ArmCount
Methadone
Methadone will be administered at a dose calculated from the subjects total daily opioid requirements, with a maximum methadone dose of 60 mg per day. The methadone will be administered every 8 hours as 5 mg capsules that will be given via an enteral feeding tube. Methadone
4
Placebo
This will be a capsule containing only lactose and will be given every 8 hours via an enteral feeding tube. The number of placebo capsules will be calculated based on the subjects opioid requirements. This will ensure the same number of capsules will be given despite which arm the patient is enrolled in. Placebo
5
Total9

Baseline characteristics

CharacteristicPlaceboTotalMethadone
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
1 Participants2 Participants1 Participants
Age, Categorical
Between 18 and 65 years
4 Participants7 Participants3 Participants
Age, Continuous37 years
STANDARD_DEVIATION 17.2
47 years
STANDARD_DEVIATION 19.4
60 years
STANDARD_DEVIATION 14.9
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
2 Participants5 Participants3 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
3 Participants4 Participants1 Participants
Region of Enrollment
United States
5 participants9 participants4 participants
Sex: Female, Male
Female
3 Participants3 Participants0 Participants
Sex: Female, Male
Male
2 Participants6 Participants4 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 5
other
Total, other adverse events
0 / 40 / 5
serious
Total, serious adverse events
0 / 40 / 5

Outcome results

Primary

Time to Extubation

The time to extubation will be calculated and compared for both groups.

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneTime to Extubation10 Days
PlaceboTime to Extubation4 Days
Secondary

Corrected QT Interval

QTc intervals will be calculated and documented at baseline and every 24 hours after to ensure it does not become prolonged. These values will be compared between groups by taking the median of the baseline and daily values.

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneCorrected QT Interval437 ms
PlaceboCorrected QT Interval457 ms
Secondary

Cumulative Antipsychotic Use

The number of doses of antipsychotic medications will be collected and compared as a surrogate marker for presumed delirium.

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneCumulative Antipsychotic Use0 doses
PlaceboCumulative Antipsychotic Use0 doses
Secondary

Cumulative Benzodiazepine Consumption

Doses of all benzodiazepines will be collected and compared between groups to determine if methadone reduces consumption.

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneCumulative Benzodiazepine Consumption260 mg midazolam
PlaceboCumulative Benzodiazepine Consumption445 mg midazolam
Secondary

Cumulative Opioid Consumption

Cumulative doses of opioids will be collected and converted to morphine equivalents for analysis.

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneCumulative Opioid Consumption473.5 mg morphine equivalents
PlaceboCumulative Opioid Consumption561 mg morphine equivalents
Secondary

Level of Sedation

Levels of pain and sedation will be assessed per institutional policy, which utilizes the Motor Agitation Assessment Scale (MAAS). Average daily scores will be collected and compared for each group. The MAAS is scored from 0 (patient unresponsive) to 6 (dangerously agitated, uncooperative patient).

Time frame: Up to 14 days

ArmMeasureValue (MEDIAN)
MethadoneLevel of Sedation3 score on a scale
PlaceboLevel of Sedation3 score on a scale

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026